Document is current
Any future updates will be listed below
-
Authors
Zawertailo, Laurie
Hendershot, Christian S.
Tyndale, Rachel F.
Le Foll, Bernard
Samokhvalov, Andriy V.
Thorpe, Kevin E.
Pipe, Andrew
Reid, Robert D.
Selby, Peter http://orcid.org/0000-0001-5401-2996
-
Funding
Funding for this research was provided by:
Canadian Cancer Society Research Institute (703187)
- License Information
-
More Information
Article History
Received: 25 May 2020
Accepted: 18 June 2020
First Online: 29 June 2020
Ethics approval and consent to participate
: The study protocol was approved by the Research Ethics Board at the Centre for Addiction and Mental Health (#039-2015). Written, informed consent will be obtained from all participants by research staff who have no clinical relationship with the patient. The study has also been approved by Health Canada Natural Products Directorate Clinical Trials Application (File number: HC6-24-c200364).
: Not applicable.
: LZ has received funding that includes salary support from Pfizer Inc. (GRAND Award) and the Health Services Research Fund from the Ontario Ministry of Health. PS declares that Johnson & Johnson, Novartis, and Pfizer Inc. are vendors of record for having provided free/discounted smoking cessation pharmacotherapy for other research studies unrelated to this study. RFT has consulted for Ethismos and Quinn Emanuel. BLF has obtained funding from Pfizer Inc. (GRAND Awards, including salary support) for investigator-initiated projects and has received a coil for TMS smoking cessation study from Brainsway. Other funding sources are not related to smoking studies. All other authors declare that they have no competing interests.
